Cowen and Company reissued their buy rating on shares of Immune Design Corp. (NASDAQ:IMDZ) in a report released on Sunday.

IMDZ has been the subject of a number of other reports. Jefferies Group reduced their price objective on shares of Immune Design Corp. from $17.00 to $15.00 and set a buy rating for the company in a research note on Thursday. Zacks Investment Research upgraded shares of Immune Design Corp. from a sell rating to a hold rating in a research note on Friday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $13.50.

Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at 8.30 on Friday. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $23.55. The company’s market capitalization is $210.89 million. The company has a 50-day moving average of $6.97 and a 200 day moving average of $8.63.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.11. Immune Design Corp. had a negative net margin of 415.05% and a negative return on equity of 50.92%. The business earned $8.20 million during the quarter, compared to analysts’ expectations of $1.73 million. Analysts forecast that Immune Design Corp. will post ($2.46) EPS for the current year.

In other Immune Design Corp. news, Director Lewis W. Coleman purchased 40,000 shares of the stock in a transaction on Tuesday, September 20th. The shares were purchased at an average price of $6.25 per share, with a total value of $250,000.00. Following the acquisition, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $312,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Group L. P. Column purchased 800,000 shares of the stock in a transaction on Tuesday, September 20th. The stock was acquired at an average cost of $6.25 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. Corporate insiders own 42.90% of the company’s stock.

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System raised its stake in shares of Immune Design Corp. by 25.1% in the third quarter. California State Teachers Retirement System now owns 29,374 shares of the company’s stock valued at $223,000 after buying an additional 5,900 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Immune Design Corp. by 11.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 254,772 shares of the company’s stock valued at $1,931,000 after buying an additional 25,226 shares during the period. BlackRock Fund Advisors raised its stake in shares of Immune Design Corp. by 18.6% in the third quarter. BlackRock Fund Advisors now owns 651,726 shares of the company’s stock valued at $4,940,000 after buying an additional 101,990 shares during the period. BlackRock Investment Management LLC raised its stake in shares of Immune Design Corp. by 26.9% in the third quarter. BlackRock Investment Management LLC now owns 53,161 shares of the company’s stock valued at $403,000 after buying an additional 11,285 shares during the period. Finally, BlackRock Advisors LLC raised its stake in shares of Immune Design Corp. by 3.8% in the third quarter. BlackRock Advisors LLC now owns 62,673 shares of the company’s stock valued at $475,000 after buying an additional 2,318 shares during the period. 47.66% of the stock is currently owned by hedge funds and other institutional investors.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.